RecruitingNot applicableNCT06796543
Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
Studying Bone sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Principal Investigator
- Sahaja Acharya, MDSKCCC Johns Hopkins Medical Institution
- Intervention
- Consolidative radiation therapy (cRT)(radiation)
- Enrollment
- 70 enrolled
- Eligibility
- 39 years · All sexes
- Timeline
- 2025 – 2030
Study locations (2)
- Sibley Memorial Hospital, Washington D.C., District of Columbia, United States
- Johns Hopkins Hospital, Baltimore, Maryland, United States
Collaborators
Clark Charitable Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06796543 on ClinicalTrials.govOther trials for Bone sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07479732Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic OsteosarcomaPeking University People's Hospital
- RECRUITINGPHASE1NCT07222735Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory SarcomasSt. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT07359053MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced SarcomaShanghai 6th People's Hospital
- RECRUITINGPHASE2NCT06939855QL1706 in the Treatment of Advanced Bone and Soft Tissue SarcomaSun Yat-sen University
- RECRUITINGNCT07215611Financial Toxicity in Patients With Resected Soft Tissue and Bone SarcomasM.D. Anderson Cancer Center
- RECRUITINGNCT06958107LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma PatientsWake Forest University Health Sciences
- RECRUITINGPHASE1, PHASE2NCT07066982Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced SarcomasEssen Biotech
- RECRUITINGPHASE1, PHASE2NCT06709495Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory SarcomasDavid S Shulman, MD